Creative Planning Boosts Holdings in Charles River Laboratories International, Inc. $CRL

Creative Planning lifted its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 7.1% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,894 shares of the medical research company’s stock after buying an additional 586 shares during the period. Creative Planning’s holdings in Charles River Laboratories International were worth $1,349,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently added to or reduced their stakes in the company. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its stake in Charles River Laboratories International by 3.0% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 12,046 shares of the medical research company’s stock worth $1,828,000 after acquiring an additional 352 shares during the last quarter. Banco Bilbao Vizcaya Argentaria S.A. lifted its stake in shares of Charles River Laboratories International by 355.3% in the 2nd quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 14,156 shares of the medical research company’s stock valued at $2,148,000 after purchasing an additional 11,047 shares during the last quarter. PNC Financial Services Group Inc. grew its holdings in shares of Charles River Laboratories International by 9.1% during the 2nd quarter. PNC Financial Services Group Inc. now owns 17,368 shares of the medical research company’s stock worth $2,635,000 after purchasing an additional 1,442 shares during the period. Allworth Financial LP increased its position in shares of Charles River Laboratories International by 172.7% during the 2nd quarter. Allworth Financial LP now owns 300 shares of the medical research company’s stock worth $45,000 after purchasing an additional 190 shares during the last quarter. Finally, ProShare Advisors LLC raised its holdings in Charles River Laboratories International by 8.0% in the 2nd quarter. ProShare Advisors LLC now owns 8,767 shares of the medical research company’s stock valued at $1,330,000 after buying an additional 653 shares during the period. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Charles River Laboratories International Stock Down 0.4%

Charles River Laboratories International stock opened at $178.14 on Friday. The firm has a market capitalization of $8.77 billion, a P/E ratio of -133.94, a P/E/G ratio of 4.83 and a beta of 1.53. The company has a current ratio of 1.36, a quick ratio of 1.10 and a debt-to-equity ratio of 0.69. Charles River Laboratories International, Inc. has a twelve month low of $91.86 and a twelve month high of $203.01. The stock’s fifty day simple moving average is $171.68 and its 200-day simple moving average is $160.05.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, November 5th. The medical research company reported $2.43 EPS for the quarter, topping the consensus estimate of $2.32 by $0.11. The firm had revenue of $1 billion during the quarter, compared to analysts’ expectations of $990.43 million. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%.Charles River Laboratories International’s revenue for the quarter was down .5% on a year-over-year basis. During the same period in the previous year, the firm posted $2.59 EPS. As a group, equities analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. Wall Street Zen lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Robert W. Baird upgraded shares of Charles River Laboratories International from a “neutral” rating to an “outperform” rating and lifted their target price for the company from $178.00 to $199.00 in a report on Thursday, November 6th. Argus set a $200.00 price target on Charles River Laboratories International in a research note on Monday, November 17th. William Blair raised Charles River Laboratories International from a “market perform” rating to an “outperform” rating in a research note on Monday, October 6th. Finally, Mizuho increased their target price on Charles River Laboratories International from $155.00 to $174.00 and gave the stock a “neutral” rating in a research note on Friday, October 17th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $190.86.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).